Ninety-six-hour starved peripheral blood mononuclear cell supernatant inhibited LA7 breast cancer stem cells induced tumor
LA7
adaptive immunity
breast cancer stem cells
cancer development
immunohistochemistry
nano-LC-ESI-MS/MS
serum starvation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
08
2022
accepted:
22
12
2022
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
The microenvironment of solid tumors such as breast cancer is heterogeneous and complex, containing different types of cell, namely, cancer stem cells and immune cells. We previously reported the immunoregulatory behavior of the human immune cell in a solid tumor microenvironment-like culture under serum starvation stress for 96 h. Here, we examined the effect of this culture-derived solution on breast cancer development in rats. Ninety-six-hour starved PBMCs supernatant (96 h-SPS) was collected after culturing human PBMCs for 96 h under serum starvation condition. Breast cancer stem cells, LA7 cell line, was used for 96 h-SPS solution reduced the LA7 cell viability, proliferation, and migration and 96 h-SPS solution may help to prevent cancer stem cell mediated tumor development. This phenomenon could be mediated through direct cytotoxic effects, inhibition of cell proliferation and migration in association with reduction in
Identifiants
pubmed: 36908807
doi: 10.3389/fimmu.2022.1025933
pmc: PMC9996193
doi:
Substances chimiques
Ki-67 Antigen
0
Gch1 protein, rat
EC 3.5.4.16
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1025933Informations de copyright
Copyright © 2023 Mehri, Gheitasi, Pourbagher, Ranaee, Nayeri, Rahimi, Khorasani, Hossein-Nattaj, Sabour, Akhavan-Niaki, Fattahi, Kalali and Mostafazadeh.
Déclaration de conflit d'intérêts
Author BK was employed by the company IGUANA BioTechnology GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Semin Cancer Biol. 2016 Oct;40-41:192-208
pubmed: 27609747
Front Pharmacol. 2018 Jun 20;9:650
pubmed: 29973879
Sci Rep. 2022 Mar 10;12(1):3966
pubmed: 35273218
Curr Pharm Biotechnol. 2011 Oct;12(10):1728-41
pubmed: 21466440
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
J Biol Chem. 2017 Mar 17;292(11):4663-4673
pubmed: 28154177
J Thorac Oncol. 2016 Jun;11(6):789-800
pubmed: 26845192
Proc Natl Acad Sci U S A. 2017 May 23;114(21):5337-5342
pubmed: 28484034
Biochim Biophys Acta. 2014 Mar;1839(3):138-54
pubmed: 24145198
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
Front Cell Dev Biol. 2022 Feb 10;10:810327
pubmed: 35223839
Medicina (Kaunas). 2018 Mar 30;54(2):
pubmed: 30344242
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Free Radic Biol Med. 2021 May 20;168:81-94
pubmed: 33781891
Nature. 2018 Nov;563(7732):564-568
pubmed: 30405245
J Oral Maxillofac Pathol. 2020 May-Aug;24(2):368-373
pubmed: 33456249
Dev Biol. 2015 Mar 1;399(1):129-138
pubmed: 25557619
Apoptosis. 2017 Nov;22(11):1321-1335
pubmed: 28936716
Gene. 2020 Apr 15;734:144381
pubmed: 31978510
Arch Biochem Biophys. 2022 Jul 15;723:109199
pubmed: 35398290
Int J Cancer. 2008 Nov 15;123(10):2229-38
pubmed: 18777559
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9932-9941
pubmed: 32312819
J Biol Chem. 2009 Oct 9;284(41):28128-28136
pubmed: 19666465
Rep Biochem Mol Biol. 2021 Apr;10(1):105-118
pubmed: 34277874
Cancer Treat Res. 2006;130:103-24
pubmed: 16610705
Trends Cancer. 2015 Dec;1(4):252-265
pubmed: 27088132
Int J Mol Sci. 2020 Dec 10;21(24):
pubmed: 33321789
Am J Pathol. 2010 Nov;177(5):2671-80
pubmed: 20847284
Tumour Biol. 2022;44(1):17-35
pubmed: 35180142
J Clin Oncol. 2005 Oct 1;23(28):7212-20
pubmed: 16192605
J Immunol. 2003 Mar 1;170(5):2340-8
pubmed: 12594256
World J Surg Oncol. 2010 May 28;8:45
pubmed: 20507643
Nat Chem Biol. 2020 Dec;16(12):1351-1360
pubmed: 32778843
Eur J Cancer Prev. 2021 May 1;30(3):275-281
pubmed: 33656837
Exp Cell Res. 2010 May 1;316(8):1324-31
pubmed: 20211171
Int J Cancer. 2013 Feb 1;132(3):591-604
pubmed: 22753274
PLoS One. 2011;6(11):e26390
pubmed: 22069448
Int Immunol. 2001 Sep;13(9):1121-7
pubmed: 11526092
Stem Cells. 2012 May;30(5):876-87
pubmed: 22311737
Free Radic Biol Med. 2017 Mar;104:214-225
pubmed: 28104455
EMBO Mol Med. 2016 Feb 19;8(3):247-67
pubmed: 26896449
Semin Cancer Biol. 2018 Dec;53:265-281
pubmed: 30317036
J Invest Dermatol. 2019 Jan;139(1):186-194
pubmed: 30009831
J Clin Oncol. 2008 Jun 10;26(17):2813-20
pubmed: 18539959
Circulation. 2014 Aug 12;130(7):593-625
pubmed: 25098323
Iran J Immunol. 2016 Mar;13(1):54-63
pubmed: 27026047
Mol Cell Oncol. 2014 Dec 03;2(2):e970489
pubmed: 27308421
Clin Cancer Res. 2009 Apr 15;15(8):2612-9
pubmed: 19351766
Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6
pubmed: 16488983
Am J Cancer Res. 2012;2(3):340-56
pubmed: 22679565
Front Cell Infect Microbiol. 2022 Jan 07;11:786994
pubmed: 35071039
Biomed Pharmacother. 2018 Dec;108:1404-1411
pubmed: 30453448
Front Immunol. 2016 Dec 20;7:621
pubmed: 28066431
Front Vet Sci. 2022 May 03;9:859025
pubmed: 35591873
Front Immunol. 2020 May 15;11:933
pubmed: 32670262
Front Oncol. 2021 Aug 27;11:720632
pubmed: 34513700
Signal Transduct Target Ther. 2020 Feb 7;5(1):8
pubmed: 32296030